Back To: Home



Xceleron, Sanofi-Aventis to address clinical development challenges
June 2007

YORK, U.K.—Xceleron announced early this month that following signature of a master services agreement with Sanofi-Aventis Deutschland GmbH, a number of studies are underway to assess the human metabolism of novel compounds in early clinical development.
According to Professor Colin Garner, Xceleron CEO, "Xceleron is delighted to be working with Sanofi-Aventis to optimize their radiolabelled clinical studies. Increasingly, leading pharmaceutical companies are adopting Xceleron's new drug development strategies to maximize data on compounds in the exploratory clinical development phase. This powerful new knowledge enables our partners to make much more informed decisions about the future clinical development of each new drug."
Dr. G. Ulrich Kuerzel, deputy head, GMPK Frankfurt and head of metabolism/in vitro systems for Sanofi-Aventis Deutschland GmbH at Frankfurt notes that "initial data we are receiving from these studies confirm our interest in using Xceleron's ultra-sensitive analytical technology—we are gaining important information that has not been available to us previously."
Xceleron's approach enables human drug-metabolite profiling to be performed in the early stages of clinical development; ideally as part of an enhanced Phase I study. This type of analysis allows drug developers to detect and measure ultra-low levels of both known and previously unknown metabolites, producing data that aren't available using other analytical techniques. The discovery of novel human-specific metabolites at the later stages of clinical development is therefore avoided with potentially significant financial savings. Early human profiling also helps identify the most suitable species for use in long-term toxicology and pharmacology studies.



1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.